Interpace Biosciences Stock Cash Flow From Operations
Fundamental analysis of Interpace Biosciences allows traders to better anticipate movements in Interpace Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Interpace |
Interpace Biosciences OTC Stock Cash Flow From Operations Analysis
Interpace Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Interpace Biosciences Cash Flow From Operations | (8.72 M) |
Most of Interpace Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Interpace Biosciences has (8.72 Million) in Cash Flow From Operations. This is 101.65% lower than that of the Health Care Providers & Services sector and 103.8% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.9% higher than that of the company.
Interpace Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in cash flow from operations category among its peers.
Interpace Fundamentals
Return On Equity | -2.85 | ||||
Return On Asset | -0.26 | ||||
Profit Margin | (0.59) % | ||||
Operating Margin | (0.28) % | ||||
Current Valuation | 11.72 M | ||||
Shares Outstanding | 4.27 M | ||||
Shares Owned By Insiders | 28.12 % | ||||
Number Of Shares Shorted | 47.35 K | ||||
Price To Earning | (1.07) X | ||||
Price To Book | 10.04 X | ||||
Price To Sales | 0.10 X | ||||
Revenue | 41.31 M | ||||
Gross Profit | 17.95 M | ||||
EBITDA | (9.12 M) | ||||
Net Income | (14.94 M) | ||||
Cash And Equivalents | 1.86 M | ||||
Cash Per Share | 0.44 X | ||||
Total Debt | 9.44 M | ||||
Debt To Equity | 6.55 % | ||||
Current Ratio | 0.61 X | ||||
Book Value Per Share | (14.51) X | ||||
Cash Flow From Operations | (8.72 M) | ||||
Short Ratio | 0.19 X | ||||
Earnings Per Share | (3.12) X | ||||
Target Price | 11.0 | ||||
Number Of Employees | 147 | ||||
Beta | 0.82 | ||||
Market Capitalization | 5.16 M | ||||
Total Asset | 38.43 M | ||||
Retained Earnings | (172.59 M) | ||||
Working Capital | (4.21 M) | ||||
Current Asset | 19.16 M | ||||
Current Liabilities | 23.37 M | ||||
Z Score | -4.6 | ||||
Net Asset | 38.43 M |
Currently Active Assets on Macroaxis
VALE | Vale SA ADR | |
EGY | Vaalco Energy | |
CMCSA | Comcast Corp | |
BTE | Baytex Energy Corp | |
SOXS | Direxion Daily Semiconductor |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |